Méchaï Frédéric, Cordel Hugues, Guglielmetti Lorenzo, Aubry Alexandra, Jankovic Mateja, Viveiros Miguel, Santin Miguel, Goletti Delia, Cambau Emmanuelle
APHP, Infectious Disease Unit, Avicenne Hospital, Université Paris 13, IAME, INSERM, Bobigny, France.
APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.
Front Public Health. 2020 Sep 4;8:443. doi: 10.3389/fpubh.2020.00443. eCollection 2020.
To evaluate and compare practices regarding the diagnosis, isolation measures, and treatment of tuberculosis (TB) in high-income countries and mainly in Europe. A survey was conducted from November 2018 to April 2019 within the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). The practices observed were compared to the main international guidelines. Among 136 ESGMYC members, 64 (17 countries) responded to the questionnaire. In their practice, two (20.7%) or three sputum samples (79.3%) were collected for the diagnosis of pulmonary TB, alternatively induced sputum ( = 37, 67.2%), bronchoscopy (34, 58.6%), and gastric aspirates (15, 25.9%). Nucleic acid amplification tests (NAATs) were performed by 41 (64%) respondents whatever the smear result and by 47 (73%) in case of smear-positive specimens. NAAT and adenosine deaminase measurement were used for extrapulmonary TB diagnosis in 83.6 and 40.4% of cases, respectively. For isolation duration, 21 respondents (42.9%) were keeping isolation until smear negativity. An initial treatment without ethambutol was offered by 14% ( = 9) of respondents. Corticosteroid therapy, cerebrospinal fluid opening pressure testing, and repeated lumbar puncture were carried out for central nervous system TB by 79.6, 51.9, and 46.3% of the respondents, respectively. For patients with human immunodeficiency virus-TB coinfection, the preferred antiretroviral therapy included dolutegravir 50 mg twice a day (56.8%). Comparing with the recommendations of the main guidelines, the practices are not totally consistent. This study shows heterogeneous practices, particularly for diagnosis, and isolation, although rapid molecular testing is implemented in most centers. More standardization might be needed.
评估和比较高收入国家(主要是欧洲国家)关于结核病(TB)诊断、隔离措施及治疗的实践情况。2018年11月至2019年4月在欧洲临床微生物学和传染病学会分枝杆菌感染研究组(ESGMYC)内开展了一项调查。将观察到的实践情况与主要国际指南进行比较。在136名ESGMYC成员中,64名(来自17个国家)回复了问卷。在他们的实践中,诊断肺结核时采集两份(20.7%)或三份痰标本(79.3%),也可采集诱导痰(n = 37,67.2%)、进行支气管镜检查(34例,58.6%)以及采集胃吸出物(15例,25.9%)。无论涂片结果如何,41名(64%)受访者会进行核酸扩增检测(NAATs),涂片阳性标本的检测比例为47名(73%)。NAAT和腺苷脱氨酶检测分别用于83.6%和40.4%的肺外结核诊断病例。对于隔离期限,21名受访者(42.9%)会持续隔离至涂片转阴。14%(n = 9)的受访者提供不含乙胺丁醇的初始治疗。分别有79.6%、51.9%和46.3%的受访者对中枢神经系统结核患者进行皮质类固醇治疗、脑脊液开放压检测以及重复腰椎穿刺。对于合并人类免疫缺陷病毒(HIV)的结核患者,首选的抗逆转录病毒疗法包括每日两次服用50毫克度鲁特韦(56.8%)。与主要指南的建议相比,这些实践并不完全一致。本研究显示实践情况存在差异,尤其是在诊断和隔离方面,尽管大多数中心都采用了快速分子检测。可能需要更多的标准化。